💸 The Tape

Bloomberg lit the fuse Wednesday night, reporting Eli Lilly was in talks to buy AtaiBeckley. By Thursday morning it was no longer a rumor: the two companies announced a definitive agreement. Lilly will pay $6.75 per share in cash, valuing AtaiBeckley's equity at roughly $2.8 billion, with a contingent value right worth up to an additional $2.50 per share (about $1 billion) tied to development and regulatory milestones for lead asset BPL-003 and follow-on VLS-01.

Do the math and the message is loud. The cash portion alone is a ~40% premium to AtaiBeckley's 30-day VWAP, and 26% above Wednesday's $5.36 close. Shares gapped up 30%+ on the open. This is the moment big pharma officially entered the psychedelic arms race — and it won't be the last deal of its kind.

The counterintuitive part

Two days ago, if you'd asked us to rank the three scaled psychedelic pure-plays — AtaiBeckley, Definium (the former MindMed), and Compass Pathways — by near-term take-out probability, AtaiBeckley would have been third. It has the earliest-stage lead asset of the group. BPL-003, an intranasal synthetic 5-MeO-DMT for treatment-resistant depression, is only in Phase 3 preparation, with initial pivotal data not expected until 2029. Compass is filing its NDA this quarter. Definium already has one positive Phase 3 in hand.

So why did the least de-risked company get bought first? Because that's exactly how the smart pharma playbook works, and it's worth internalizing if you're trading this sector.

Lilly didn't pay a full, launch-ready premium. It bought optionality at a discount and structured the deal to push risk back onto sellers. BPL-003 carries FDA Breakthrough Therapy Designation and produced genuinely strong Phase 2 numbers — a single 10mg intranasal dose drove a ~12.6-point MADRS reduction by Day 2 that held to Day 85. But the pivotal readout is years out. Rather than pay up for certainty, Lilly paid a modest cash premium now and loaded the upside into a CVR that only pays if BPL-003 and VLS-01 actually deliver. It's a way to bridge the valuation gap between what a seller wants and what a buyer will underwrite: you take the base case in cash, and the bull case becomes a coupon you only clip if the science works.

Just as important, Lilly wasn't buying a single molecule. AtaiBeckley is a platform of rapid-acting neuroplastogens — BPL-003, plus VLS-01 (DMT buccal film) and EMP-01 (R-MDMA) — with a discovery engine behind it. For a company already spending upward of $10 billion (potentially $25 billion) across eight acquisitions in its current M&A spree, a $2.8B upfront bolt-on that broadens the neuroscience franchise into TRD and hard-to-treat psychiatric disorders is a rounding error with asymmetric payoff. Lilly gets a beachhead in the category for the price of a single-asset premium.

What it means for the two companies still standing

The deal doesn't just reprice AtaiBeckley. It sets a comp for the entire space — and puts a spotlight on Compass and Definium as the two remaining independent pure-plays of real scale.

Compass Pathways (CMPS) is the closest thing to a launchable product in psychedelics. COMP360, its synthetic psilocybin, cleared both pivotal trials (COMP005 and COMP006), with durable six-month benefit and a differentiated rapid-onset profile in TRD. It holds a rolling NDA, a Commissioner's National Priority Voucher, and expects to complete its filing in Q4 — launch-ready by year-end, commercial launch targeted for the first half of 2027. It's sitting on roughly $466 million in cash.

Here's the nuance the Lilly deal creates: Compass just became more valuable and more expensive at the same time. More valuable because a marquee acquirer validated the whole thesis and the Street already frames Compass as a target for CNS-hungry buyers — J&J (obvious Spravato synergy in interventional psychiatry), AbbVie, and AstraZeneca all get named. More expensive because "closest to launch" means the premium to take it out is the richest in the group. If Lilly's move was about buying cheap optionality, a Compass deal is the opposite trade — paying up for a de-risked, near-revenue asset. Both can be rational for different buyers.

Definium (DFTX) is the higher-beta bet and, in our read, the most likely next domino. Its LSD-derived DT120 ODT posted the best raw efficacy signal in the sector — the Phase 3 Emerge study in MDD showed an 8.1-point placebo-adjusted MADRS improvement (p<0.0001), materially larger than the psilocybin numbers, with the effect still significant at Week 12. Definium is also the only one of the three attacking both MDD and GAD at pivotal stage (DT120 has Breakthrough Therapy Designation in GAD), with two more Phase 3 readouts — Panorama and Voyage — due in Q3 2026, plus the confirmatory Ascend MDD trial. It's cheaper than Compass and carries ~$373 million in cash into 2028.

The swing factor is those Q3 readouts. A single positive Phase 3 still leaves replication risk that disciplined acquirers discount. But if Ascend and the GAD trials hit, Definium arguably leapfrogs Compass on strategic value, because LSD-derived DT120 addresses broader primary-care-adjacent populations than a TRD-first psilocybin. That data is the next catalyst worth pre-positioning around.

The re-rank

For a take-out today, our order on the remaining field:

1. Compass — most de-risked, most strategically obvious, richest premium. J&J is the name to watch.

2. Definium — highest upside, one confirmatory dataset from being fully in play. Q3 GAD/Ascend data is the trigger.

AtaiBeckley is off the board. The uncomfortable truth for anyone who ranked it last: the market's read on "acquirability" conflated time-to-revenue with deal-readiness, and pharma just showed us those aren't the same thing. Buyers will pay for platform and early optionality when the price is right — they don't wait for the finish line.

The bigger picture

This is the tailwind the sector has waited a decade for. Layer in the executive order directing the DEA to fast-track review of psychedelic treatments that complete Phase 3, and the setup is clear: a legitimizing acquirer, a regulatory on-ramp, and two obvious next targets with catalysts on the calendar.

For years, psychedelic investing sat on the fence between "will it work" and "will anyone pay for it." Lilly just answered the second question with $2.8 billion. Expect the list of buyers to grow from here, not shrink.

📈 Dog Walkers

$CMPS ( ▼ 0.6% ) Publishes Critical Data

Compass Pathways just published data that answers one of the most consequential questions hanging over its regulatory path: is COMP360 a drug, or is it drug-assisted therapy?

According to a new post-hoc analysis published in the Journal of Psychopharmacology, the answer is unambiguous — it's the drug. The analysis of support methods in Compass's open-label Phase 2 PTSD study found that 78% of administration sessions were spent in silence, with interactions between patients and support providers described as minimal, non-directive, and largely outside patients' awareness during treatment.

Chief Medical Officer Dr. Guy Goodwin drew the line explicitly: "It is incorrect to describe the treatment we are developing as psilocybin-assisted psychotherapy." The findings, he said, reinforce that the rapid and durable symptom improvement observed in the trial "was attributable to the psilocybin drug experience" — with support providers serving as reassuring presence rather than active therapeutic participants.

The regulatory significance is substantial. The FDA approves drugs, not psychotherapy protocols — and the entanglement of drug effect with therapist-driven intervention was a central complication in Lykos Therapeutics' failed MDMA application in 2024. By demonstrating that patients "self-navigate" the experience with only reassurance and physical proximity as support, Compass strengthens the case that COMP360's efficacy is pharmacological, measurable, and replicable — exactly what regulators need to see.

With 26-week durability data expected this quarter and a rolling NDA submission targeted for Q4, Compass is systematically clearing the obstacles that stalled its predecessors. The silence in those treatment rooms may end up speaking loudest at the FDA.

$AVTBF ( ▲ 5.83% ) Reports Q2

Avant Brands delivered a quarter that requires reading past the headline numbers — because the story underneath is one of deliberate short-term pain for long-term positioning.

The ultra-premium Canadian producer reported Q2 2026 net revenue of $7.8 million, down 8% year-over-year, with adjusted EBITDA swinging to negative $1.2 million from positive $1.2 million a year ago. But the declines weren't demand-driven — they were self-inflicted by design. Avant took staggered room closures at its Flowr facility, its largest, to execute a nearly $2 million capital improvement program converting the entire facility to high-efficiency LED lighting — upgrades designed to cut electrical demand, increase capacity per square foot, and elevate product quality. Notably, $1.8 million in government grant proceeds directly funded the project — non-dilutive capital that most small-caps can only dream about.

Where demand showed up, it showed up loudly. Recreational revenue jumped 31% in the quarter and is up 34% year-to-date, driven by dominant Ontario market positions: BLK MKT™ ranked #1 in premium flower ($8.60+/gram) — outperforming more than 60 competing brands — and held the #1 spot in single pre-rolls above 1 gram. Tenzo™ claimed the #2 best-selling 14-gram SKU in the province and the #1 multi-pack milled product.

The balance sheet work is equally striking. CEO Norton Singhavon highlighted that Avant has eliminated nearly 90% of its total debt in under 24 months — from $8.1 million to just $1.03 million — while cash more than doubled to $3.3 million and the company generated $1.7 million in operating cash flow over six months.

The export wholesale decline (-29%) bears watching, and negative EBITDA is never comfortable. But a company with category-leading brands, near-zero debt, positive operating cash flow, and freshly upgraded capacity heading into the second half looks a lot like one that traded a rough quarter for a stronger multi-year setup.

📺 Trade To Black

ALJ Hearing Is Officially Over | TTB Presented by Flowhub

• Anticlimactic Finish: The ALJ hearing's final day wrapped surprisingly early at 12 PM Eastern with no dramatic exchanges or late-breaking developments — closing the evidentiary record on the sixteen-day proceeding, with Gretchen Gailey reporting the final details from Arlington.

• States' Closing Witnesses: Nebraska, Idaho, and Indiana presented the final testimony, calling Dr. Deepak D'Souza — a VA psychiatrist and Yale School of Medicine professor — to reinforce their scientific opposition to rescheduling.

• The Illicit Market Argument: Second witness Sheriff William Honsal of Humboldt County challenged the premise that legalization is the fastest way to eliminate the illicit market — drawing on his experience in California's most notorious unlicensed cultivation region.

• Now We Wait: With the record officially closed, the process moves to post-hearing briefs and the ALJ's recommended decision to the DEA — the findings that will determine whether all marijuana follows medical cannabis to Schedule III and shape the next phase of federal policy.